Success Metrics

Clinical Success Rate
94.5%

Based on 240 completed trials

Completion Rate
94%(240/254)
Active Trials
14(5%)
Results Posted
43%(104 trials)
Terminated
14(5%)

Phase Distribution

Ph not_applicable
23
8%
Ph phase_3
75
25%
Ph phase_1
54
18%
Ph early_phase_1
3
1%
Ph phase_2
51
17%
Ph phase_4
77
25%

Phase Distribution

57

Early Stage

51

Mid Stage

152

Late Stage

Phase Distribution283 total trials
Early Phase 1First-in-human
3(1.1%)
Phase 1Safety & dosage
54(19.1%)
Phase 2Efficacy & side effects
51(18.0%)
Phase 3Large-scale testing
75(26.5%)
Phase 4Post-market surveillance
77(27.2%)
N/ANon-phased studies
23(8.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.0%

240 of 261 finished

Non-Completion Rate

8.0%

21 ended early

Currently Active

14

trials recruiting

Total Trials

306

all time

Status Distribution
Active(14)
Completed(240)
Terminated(21)
Other(31)

Detailed Status

Completed240
unknown31
Terminated14
Recruiting8
Withdrawn7
Active, not recruiting6

Development Timeline

Analytics

Development Status

Total Trials
306
Active
14
Success Rate
94.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (1.1%)
Phase 154 (19.1%)
Phase 251 (18.0%)
Phase 375 (26.5%)
Phase 477 (27.2%)
N/A23 (8.1%)

Trials by Status

completed24078%
unknown3110%
terminated145%
withdrawn72%
recruiting83%
active_not_recruiting62%

Recent Activity

Clinical Trials (306)

Showing 20 of 306 trialsScroll for more
NCT04775082Phase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Active Not Recruiting
NCT04575844Phase 4

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Recruiting
NCT03856632Phase 4

Liraglutide Effect in Atrial Fibrillation

Active Not Recruiting
NCT02944500Phase 4

Saxenda: Underlying Mechanisms and Clinical Outcomes

Active Not Recruiting
NCT05965908Phase 3

Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome

Completed
NCT05681299Phase 4

Effects of GH and Lirglutide on AgRP

Recruiting
NCT02674893Phase 4

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

Terminated
NCT02721888Phase 4

Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Terminated
NCT07225816Phase 1

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Recruiting
NCT05579249Phase 4

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
NCT06283641

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Completed
NCT05313529Not Applicable

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Active Not Recruiting
NCT07029009Phase 2

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Recruiting
NCT07244003Phase 4

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Recruiting
NCT05756764

Anti-obesity Pharmacotherapy and Inflammation

Active Not Recruiting
NCT02879409Not Applicable

HbA1c Variability in Type II Diabetes

Active Not Recruiting
NCT02516657Phase 3

Liraglutide in Adolescents With Type 1 Diabetes

Completed
NCT03158805Phase 2

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Completed
NCT04881110Phase 4

Liraglutide and Peripheral Artery Disease

Completed
NCT06818292Not Applicable

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

Completed

Drug Details

Intervention Type
DRUG
Total Trials
306